Showing results (571-580 of 595) with videos related to
Sort By:
Pageof 60
Circulation Research|November 9, 2016
PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMIArshed A Quyyumi, Alejandro Vasquez, Dean J Kereiakes, et al.Journal of the Society for Cardiovascular Angiography & Interventions|July 18, 2022
North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital MortalityPayam Dehghani, Christian W Schmidt, Santiago Garcia, et al.Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.The Journal of Rheumatology|January 15, 2025
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile SpondyloarthritisAdam Mayer, Timothy G Brandon, Amita Aggarwal, et al.Circulation|June 15, 2007
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trialDouglas W Losordo, Richard A Schatz, Christopher J White, et al.American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 9, 2020
Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United StatesSantiago Garcia, Larissa Stanberry, Christian Schmidt, et al.Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art ReviewNathaniel R Smilowitz, Megha Prasad, R Jay Widmer, et al.Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.Pageof 60